Acute pancreatitis caused by tipranavir/ritonavir-induced hypertriglyceridaemia [3]

AIDS

Volumn 21, Issue 4, 2007, Pages 532-533

  Chapman, Scott J R ^a   Woolley, Ian J ^a   Visvanathan, Kumar ^a   Korman, Tony M ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ATAZANAVIR; EFAVIRENZ; FENOFIBRATE; GEMFIBROZIL; LAMIVUDINE; RITONAVIR; TENOFOVIR; TIPRANAVIR;

ACUTE PANCREATITIS; ADULT; ALCOHOL CONSUMPTION; CASE REPORT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPIGASTRIC PAIN; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; LETTER; MALE; PRIORITY JOURNAL; ULTRASOUND;

ACUTE DISEASE; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV PROTEASE INHIBITORS; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; PANCREATITIS; PYRIDINES; PYRONES; RITONAVIR;

EID: 33847068323     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328018756a     Document Type: Letter

References (12)

1. Dutta SK, Ting CD, Lai LL. Study of prevalence, severity, and etiological factors associated with acute pancreatitis in patients infected with human immunodeficiency virus. Am J Gastroenterol 1997; 92:2044-2048.
2. Dassopoulos T, Ehrenpreis ED. Acute pancreatitis in human immunodeficiency virus-infected patients: a review. Am J Med 1999; 107:78-84.
3. Reisler RB, Murphy RL, Redfield RR, Parker RA. Incidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS clinical trials group studies: lessons learned. J Acquir Immune Defic Syndr 2005; 39:159-166.
4. Bush ZM, Kosmiski LA. Acute pancreatitis in HIV-infected patients: are etiologies changing since the introduction of protease inhibitor therapy? Pancreas 2003; 27:e1-e5.
5. Food and Drug Administration. Labelling information. Available at: http://www/fda.gov/cder/foi/label/2005/02181.pdf. 2005. Accessed; 15 September 2006.
6. Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999; 100:700-705.
7. Echevarria KL, Hardin TC, Smith JA. Hyperlipidemia associated with protease inhibitor therapy. Ann Pharmacother 1999; 33:859-863.
8. Sullivan AK, Feher MD, Nelson MR, Gazzard BG. Marked hypertriglyceridaemia associated with ritonavir therapy. AIDS 1998; 12:1393-1394.
9. Sullivan AK, Nelson MR. Marked hyperlipidaemia on ritonavir therapy. AIDS 1997; 11:938-939.
10. Perry RC, Cushing HE, Deeg MA, Prince MJ. Ritonavir, triglycerides, and pancreatitis. Clin Infect Dis 1999; 28:161-162.
11. Routy JP, Smith GH, Blank DW, Gilfix BM. Plasmapheresis in the treatment of an acute pancreatitis due to protease inhibitor-induced hypertriglyceridemia. J Clin Apher 2001; 16:157-159.
12. Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in Multi-drug Resistant Patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006; 368:466-475.